Cargando…

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment

Oncolytic herpes simplex viruses (oHSVs) have demonstrated efficient lytic replication in human glioblastoma tumors using immunodeficient mouse models, but early-phase clinical trials have reported few complete responses. Potential reasons for the lack of efficacy are limited vector potency and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Joseph W., Hall, Bonnie L., Marzulli, Marco, Shah, Vrusha K., Bailey, Lisa, Chiocca, E. Antonio, Goins, William F., Kohanbash, Gary, Cohen, Justus B., Glorioso, Joseph C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430372/ https://www.ncbi.nlm.nih.gov/pubmed/34553031 http://dx.doi.org/10.1016/j.omto.2021.07.009

Ejemplares similares

GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival
por: Sette, Paola, et al.
Publicado: (2019)

Novel mutations in U(L)24 and gH rescue efficient infection of an HSV vector retargeted to TrkA
por: Marzulli, Marco, et al.
Publicado: (2023)

IM-4 Impact of oHSV activated NOTCH signaling in tumor microenvironment and its impact on anti-tumor immunity
por: Yoshihiro, Otani, et al.
Publicado: (2021)

Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes
por: Miyagawa, Yoshitaka, et al.
Publicado: (2017)

An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain
por: Reinhart, Bonnie, et al.
Publicado: (2016)

Detection of circulating tumor cells using oHSV1‐hTERT‐GFP in lung cancer
por: Gao, Hongjun, et al.
Publicado: (2017)

esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation
por: Swanner, Jessica, et al.
Publicado: (2023)

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies
por: Tuzmen, Ceren, et al.
Publicado: (2020)

STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation
por: Lee, Joel M., et al.
Publicado: (2019)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells
por: Hall, Bonnie L., et al.
Publicado: (2020)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
por: Zhang, Wen, et al.
Publicado: (2020)

Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early Genes
por: Kuroda, Seiji, et al.
Publicado: (2020)

Engineered HSV vector achieves safe long-term transgene expression in the central nervous system
por: Verlengia, Gianluca, et al.
Publicado: (2017)

A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors
por: Marzulli, M, et al.
Publicado: (2018)

Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System
por: Artusi, Sara, et al.
Publicado: (2018)

MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats
por: Iida, Takafumi, et al.
Publicado: (2017)

A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4
por: Zhang, Wen, et al.
Publicado: (2015)

USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells
por: Lu, Ruitao, et al.
Publicado: (2021)

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
por: Leddon, Jennifer L, et al.
Publicado: (2015)

Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line
por: Vannini, Andrea, et al.
Publicado: (2021)

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus
por: Reinhart, Bonnie, et al.
Publicado: (2012)

HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain
por: Hao, Shuanglin, et al.
Publicado: (2006)

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
por: Han, Jianfeng, et al.
Publicado: (2015)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Constitutive Expression of GATA4 Dramatically Increases the Cardiogenic Potential of D3 Mouse Embryonic Stem Cells
por: Laemmle, Lillian L., et al.
Publicado: (2016)

Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectors
por: Kuroda, Seiji, et al.
Publicado: (2022)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
por: Koch, Marilin S., et al.
Publicado: (2020)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
por: Okemoto, Kazuo, et al.
Publicado: (2013)

Molecular docking analysis of a secondary metabolite with the glycoprotein receptors of HSV 1 and HSV 2
por: Saran, Natarajan, et al.
Publicado: (2019)

Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy
por: Jenner, Adrianne L., et al.
Publicado: (2022)

Structural basis for capsid recruitment and coat formation during HSV-1 nuclear egress
por: Draganova, Elizabeth B, et al.
Publicado: (2020)

A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals
por: Dropulic, Lesia, et al.
Publicado: (2017)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
por: Frederico, Stephen C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vqlu3or6j3q9o9umot7aik1s0l